The short answer
The literature is dominated by preclinical work from the University of Zagreb group led by Predrag Sikirić, spanning gastrointestinal, tendon, ligament and vascular models. Clinical development occurred as PL-14736 for inflammatory bowel disease, and a Phase 2 trial is currently recruiting.
Key facts
- Dominant source
- Zagreb group (Sikirić and colleagues)
- Evidence type
- Predominantly rodent models
- Clinical development
- As PL-14736, for IBD
- Phase 1
- NCT02637284, 42 healthy volunteers
- Phase 2 now
- NCT07437547, 120 participants, recruiting
- Independent replication
- Limited
The shape of the evidence
Three tiers. A large preclinical literature, overwhelmingly in rats, covering gastrointestinal lesions, tendon and ligament models, vascular effects and more. An earlier clinical development programme under the code PL-14736. And one registered, placebo-controlled Phase 2 trial currently recruiting. Most research peptides have only the first tier; BPC-157 has all three, which is unusual.
The concentration of authorship
A substantial share of the preclinical literature originates from one group at the University of Zagreb. As with Pickart and GHK-Cu, this should be said clearly: sustained single-group work produces depth and preserves knowledge, and it also means the evidence is less independent than the paper count suggests, because shared methods and assumptions propagate through it. Independent replication is what converts findings into established results, and here it is limited.
Research material referenced
BPC-157 5mg, third-party HPLC tested
What the clinical development tells you
A compound reaching Phase 1 and Phase 2 has passed the point where someone was willing to fund manufacturing to clinical standard, assemble a safety package and enrol human subjects under regulatory oversight. That is a meaningful filter. What it does not tell you is whether the compound works. Trials exist to answer that question, and the current one has not reported.
The status field worth reading correctly
NCT02637284, the Phase 1 study, carries status UNKNOWN on ClinicalTrials.gov. That means the record has not been verified by its sponsor recently; it does not mean the study failed, was withdrawn or found anything adverse. Reading UNKNOWN as a negative result is a common misinterpretation of registry data.
How to search it
PubMed indexes the field under BPC 157 and pentadecapeptide BPC. The development codes PL-14736 and PLD-116 surface the clinical literature that the compound name misses, just as thymosin beta-4 surfaces what TB-500 misses. ClinicalTrials.gov should be searched directly rather than relied on through secondary sources, because trial status changes.
Frequently asked questions
Has BPC-157 been tested in humans?
Yes. It entered clinical development as PL-14736 for inflammatory bowel disease, a Phase 1 study was registered, and a Phase 2 trial is currently recruiting.
What does UNKNOWN status mean on a trial record?
That the sponsor has not verified the record recently. It is not a statement about outcome, and reading it as failure is a misinterpretation.
Is the preclinical work independently replicated?
Limited. A substantial share originates from one group at the University of Zagreb, which makes the evidence less independent than the volume suggests.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- TrialClinicalTrials.gov: PCO-02 Phase 1 (NCT02637284)clinicaltrials.gov
- PubMedSikiric P et al., BPC 157 in trials for inflammatory bowel disease. Inflammopharmacology 2006 (PMID 17186181)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- The Zagreb Research ProgrammePredrag Sikirić and colleagues at the University of Zagreb have produced most of the BPC-157 literature over three decades. What that concentration means.
- BPC-157 CAS Number and Chemical IdentityCAS 137525-51-0, PubChem CID 9941957, 1419.5 Da. Unlike some research peptides, BPC-157's identifiers are unambiguous - and they check out.
- BPC-157 Molecular Weight: 1419.5 Da1419.5 Da for C62H98N16O22, verified against PubChem CID 9941957. Why this figure is stable across sources when others in the field are not.
- BPC-157 vs TB-500 ComparedDifferent origins, sizes, mechanisms and evidential positions. BPC-157 has registered clinical trials; TB-500's literature largely concerns its parent protein.
- BPC-157 Structure and SequenceGEPPPGKPADDAGLV: fifteen residues, four prolines, three glycines, no cysteine or methionine and no aromatic residue. What that composition implies.